Related Experiment Video

Updated: Jun 20, 2026

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors
07:57

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors

Published on: January 20, 2023

Withaferin A targets heat shock protein 90 in pancreatic cancer cells

Yanke Yu1, Adel Hamza, Tao Zhang

  • 1Department of Pharmaceutical Sciences, College of Pharmacy, The University of Michigan, 428 Church Street, Ann Arbor, MI 48109, USA.

Biochemical Pharmacology
|September 23, 2009
PubMed

Insights

Withaferin A (WA) effectively inhibits pancreatic cancer growth by targeting heat shock protein 90 (Hsp90). This natural compound induces cancer cell death and reduces tumor size in vivo, offering a potential new therapeutic strategy.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Pancreatic cancer remains a significant health challenge with limited effective treatments.
  • Heat shock protein 90 (Hsp90) is a molecular chaperone crucial for the stability and function of numerous oncoproteins.
  • Targeting Hsp90 is a promising strategy for cancer therapy.

Purpose of the Study:

  • To investigate the anticancer efficacy of Withaferin A (WA), a natural compound from Withania somnifera.
  • To elucidate the mechanism by which WA inhibits Hsp90 in pancreatic cancer cells.
  • To evaluate the in vitro and in vivo effects of WA on pancreatic cancer progression.

Main Methods:

  • In vitro antiproliferative assays and apoptosis analysis (Annexin V staining) on pancreatic cancer cell lines.
  • Western blotting to assess Hsp90 client protein levels and proteasomal degradation.
  • Biochemical assays including WA-biotin pull-down and co-immunoprecipitation to determine WA binding site and interaction disruptions.
  • In vivo studies using pancreatic cancer xenografts in mice to evaluate tumor growth inhibition.

Main Results:

  • Withaferin A demonstrated potent antiproliferative activity against pancreatic cancer cells (IC50s 1.24-2.93 microM) and induced significant apoptosis.
  • WA inhibited Hsp90 chaperone activity, leading to the degradation of Hsp90 client proteins (Akt, Cdk4, glucocorticoid receptor) via a proteasome-dependent pathway.
  • WA binds to the C-terminus of Hsp90 through an ATP-independent mechanism and disrupts Hsp90-Cdc37 complexes.
  • WA treatment significantly inhibited pancreatic tumor growth in vivo by 30-58%.

Conclusions:

  • Withaferin A is a potent inhibitor of Hsp90 chaperone activity in pancreatic cancer.
  • WA exhibits significant anticancer effects both in vitro and in vivo, making it a potential therapeutic candidate.
  • The mechanism involves direct binding to Hsp90, disruption of key protein complexes, and subsequent client protein degradation.

More Related Videos

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics08:29

Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics

Published on: October 2, 2014

Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma05:44

Isolation of Proximal Fluids to Investigate the Tumor Microenvironment of Pancreatic Adenocarcinoma

Published on: November 5, 2020

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...